Stephens analyst Jacob Johnson lowered the firm’s price target on BioLife Solutions to $22 from $29 and keeps an Overweight rating on the shares. The firm said that divesting freezer assets is a “notable” step forward, and continues to view this as a key catalyst to unlock value at BioLife. Stephens added, however, that the company reported a Q2 revenue miss and lowered FY23 guidance for a “myriad” of reasons.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLFS:
- BioLife Solutions price target lowered to $25 from $34 at Lake Street
- BioLife Solutions price target lowered to $25 from $29 at TD Cowen
- BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business
- BLFS Upcoming Earnings Report: What to Expect?
- BioLife Solutions price target raised to $29 from $27 at Stephens
